Keywords
Biography
I graduated with a Bachelor of Medicine Bachelor of Surgery with Honours Class 1 in 2011 from UNSW Sydney. I obtained a Fellowship of the Royal Australasian College of Physicians as a specialist endocrinologist in 2018. I work as an endocrinologist in St Vincent's Clinic. I have a Master of Medicine (Clinical Epidemiology) from the University of Sydney (2019). I am finishing a PhD through the Garvan Institute of Medical Research, UNSW about...view more
I graduated with a Bachelor of Medicine Bachelor of Surgery with Honours Class 1 in 2011 from UNSW Sydney. I obtained a Fellowship of the Royal Australasian College of Physicians as a specialist endocrinologist in 2018. I work as an endocrinologist in St Vincent's Clinic. I have a Master of Medicine (Clinical Epidemiology) from the University of Sydney (2019). I am finishing a PhD through the Garvan Institute of Medical Research, UNSW about the effective and safe use of sodium-glucose cotransporter 2 inhibitors. I am a Research Associate in the Medicines Intelligence Research Program in the School of Population Health, UNSW Sydney.
My Grants
2023 UNSW Cardiac, Vascular and Metabolic Medicine Theme Collaborative Grant, $30,000
My Qualifications
Bachelor of Medicine Bachelor of Surgery Honours Class 1, UNSW Sydney (2011)
Fellow of the Royal Australasian College of Physicians (Adult Medicine Division - specialist endocrinologist) (2018)
Master of Medicine (Clinical Epidemiology), University of Sydney (2019)
My Awards
2023 UNSW Cardiac, Vascular and Metabolic Medicine Theme Symposium Best Oral Presentation
My Research Activities
As an endocrinologist, I have a strong clinical and academic interest and expertise in diabetes pharmacotherapy, specifically medicines with major cardiac and renal benefits - sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA). I have explored the implementation of SGLT2i through a mixed-methodology approach, having both undertaken novel qualitative and pharmacoepidemiology studies. As a member of the Medicines Intelligence Research Program, I have explored the uptake of SGLT2i and GLP-1 RA in people with type 2 diabetes in New South Wales and Australia. These projects have shown a considerable underutilisation of these cardiorenal medicines, as well as geographic variation in their use. We are expanding our implementation studies about these medicines.
I also have an interest in the perioperative management of people using SGLT2i and GLP-1 RA, and have published reviews and works on this subject.
Contact
ORCID as entered in ROS
https://orcid.org/0009-0002-0538-2661